Tonix Pharma Financial Statements
Tonix Pharma Financial Overview
Tonix Pharma's market cap is currently ―. The company's EPS TTM is $-7.608; its P/E ratio is -0.21; Tonix Pharma is scheduled to report earnings on August 15, 2022, and the estimated EPS forecast is $-1.45. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ ― | $ ― | $ ― | $ ― | $ ― |
| EBIT | $ -26.44M | $ -29.48M | $ -18.54M | $ -23.56M | $ -20.74M |
| EBITDA | $ -26.37M | $ -29.45M | $ -18.52M | $ -23.55M | $ -20.73M |
| Net Income Common Stockholders | $ -26.42M | $ -29.55M | $ -18.53M | $ -23.55M | $ -20.65M |
| Balance Sheet | |||||
| Cash Cash Equivalents And Short Term Investments | $ 55.66M | $ 77.07M | $ 140.44M | $ 164.21M | $ 165.72M |
| Total Assets | $ 223.72M | $ 240.90M | $ 214.77M | $ 189.16M | $ 183.52M |
| Total Debt | $ 791.00K | $ 864.00K | $ 994.00K | $ 1.07M | $ 1.13M |
| Net Debt | $ -54.87M | $ -76.20M | $ -139.44M | $ -163.15M | $ -164.59M |
| Total Liabilities | $ 15.76M | $ 22.18M | $ 12.56M | $ 8.67M | $ 6.61M |
| Stockholders Equity | $ 62.57M | $ 87.65M | $ 176.92M | $ 180.49M | $ 202.22M |
| Cash Flow | |||||
| Free Cash Flow | $ -51.26M | $ -48.07M | $ -20.70M | $ -20.54M | $ -21.56M |
| Operating Cash Flow | $ -31.05M | $ -22.45M | $ -12.95M | $ -19.11M | $ -21.06M |
| Investing Cash Flow | $ -20.22M | $ -25.62M | $ -7.75M | $ -1.43M | $ -505.00K |
| Financing Cash Flow | $ 13.06M | $ 43.77M | $ 37.96M | $ 22.05M | $ 108.71M |